Solid Tumors
📧 Sign up to get email alerts when something new happens for Solid Tumors.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-07-16Clinical Trial Update: A Study of the RNA Tumor Vaccine Targeting MICA/B in Patients With Advanced Solid Tumors [EARLY_Phase 1]
An early-phase (Phase 1) clinical trial update for an RNA vaccine targeting MICA/B in patients with advanced solid tumors; the study is curr…
-
CLINICAL_TRIALS trial_result · 2025-07-14Clinical Trial Update: Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)
PRISMM evaluates immunotherapy guided by spliceosome mutational markers in patients with metastatic solid tumors carrying SF3B1, U2AF1, or S…
-
CLINICAL_TRIALS research · 2025-07-11Clinical Trial Update: A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation [Phase 1, Phase 2]
Clinical trial update for NTS071 in TP53 Y220C-mutant advanced solid tumors, assessing safety, tolerability, and preliminary efficacy in a P…
-
CLINICAL_TRIALS research · 2025-07-11Clinical Trial Update: Comparing the Impact of Four Types of Meditation Practices for Relaxation in Cancer Survivors [NA]
A clinical trial update indicates a recruiting study comparing four meditation practices for relaxation in cancer survivors.
-
CLINICAL_TRIALS trial_result · 2025-07-10Clinical Trial Update: Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors [Phase 1]
A Phase 1 feasibility study assessing individual pharmacokinetic-guided dosing of sunitinib in patients with advanced solid tumors.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-07-10Clinical Trial Update: A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies [Phase 1]
Phase 1 clinical trial evaluating M3T01 as a monotherapy and in combination with pembrolizumab and other systemic therapies for advanced sol…
-
CLINICAL_TRIALS research · 2025-07-09Clinical Trial Update: A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors [Phase 1, Phase 2]
STAR0602, a bifunctional TCR-targeting antibody-fusion, is being studied in a Phase 1/2 trial for advanced solid tumors and related female g…
-
CLINICAL_TRIALS trial_result · 2025-07-03Clinical Trial Update: Study of ASTX029 in Subjects With Advanced Solid Tumors [Phase 1, Phase 2]
Taiho Oncology conducted a Phase 1/2 study of ASTX029 in adults with advanced solid tumors. The trial is completed and results have been pos…
-
CLINICAL_TRIALS trial_result · 2025-07-03Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors [Phase 1]
Phase 1 study evaluating safety, pharmacokinetics, and anti-tumor activity of GDC-1971 in combination with atezolizumab in locally advanced …
-
CLINICAL_TRIALS research · 2025-07-03Clinical Trial Update: 68Ga-GP-01 Injection in Solid Tumors Participants [Phase 1]
Phase 1 trial update for 68Ga-GP-01 Injection in solid tumors; the study is not yet recruiting.
-
CLINICAL_TRIALS research · 2025-07-03Clinical Trial Update: Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors [Phase 1]
This Phase 1 clinical trial from AbbVie tests ABBV-637 alone or in combination with intravenous docetaxel or osimertinib in adults with rela…
-
CLINICAL_TRIALS trial_result · 2025-07-02Clinical Trial Update: TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers [Phase 1]
Phase 1 study results for TTX-030 as a single agent and in combination with immunotherapy or chemotherapy in patients with advanced solid tu…
-
CLINICAL_TRIALS research · 2025-07-02Clinical Trial Update: A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1706) in the Treatment of Locally Advanced or Metastatic Solid Tumors
This is a multicenter, prospective real-world study evaluating iparomlimab and tuvonralimab (QL1706) for locally advanced or metastatic soli…
-
CLINICAL_TRIALS trial_result · 2025-06-29Clinical Trial Update: Biological Age Predicts 90-Day Mortality in Advanced Cancer
This completed trial suggests that biological age can predict 90-day mortality in patients with advanced cancer.
-
CLINICAL_TRIALS research · 2025-06-29Clinical Trial Update: Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients [Phase 2]
Phase 2 clinical trial update on Romiplostim (N01) for chemotherapy-induced thrombocytopenia in pediatric cancer patients; the study is curr…
-
CLINICAL_TRIALS research · 2025-06-29Clinical Trial Update: A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer [Phase 1]
A Phase I safety and pharmacokinetic study of intravenously administered Gamitrinib in patients with advanced cancer is ongoing, including l…
-
CLINICAL_TRIALS trial_result · 2025-06-27Clinical Trial Update: A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7 [Phase 1]
A Phase 1 study of NPX267 in subjects with solid tumors expressing HHLA2/B7-H7 is currently suspended. Sponsor: NextPoint Therapeutics, Inc.
-
CLINICAL_TRIALS research · 2025-06-26Clinical Trial Update: The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
A clinical trial update describes developing an 18F-G1 PET/CT tracer targeting Granzyme B for pan-cancer immunotherapy, with the study curre…
-
CLINICAL_TRIALS trial_result · 2025-06-26Clinical Trial Update: The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer [Phase 1]
Phase 1 clinical trial evaluating multiple doses of WJ01024 in patients with advanced cancer was terminated; the study assessed safety and e…
-
CLINICAL_TRIALS trial_result · 2025-06-25Clinical Trial Update: A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) [Phase 1]
Phase 1 study of MK-0482 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors has completed, repo…
-
CLINICAL_TRIALS research · 2025-06-25Clinical Trial Update: A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
A Century Therapeutics-sponsored clinical trial for participants previously treated with Century Therapeutics' cellular therapy product is c…
-
CLINICAL_TRIALS trial_result · 2025-06-25Clinical Trial Update: A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors [Phase 1]
Phase 1 dose-escalation and expansion study of XL495 in locally advanced or metastatic solid tumors has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-06-24Clinical Trial Update: A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b [Phase 1]
A first-in-human Phase 1 trial evaluating safety, tolerability, and pharmacokinetics of DS-6051b in solid tumors has completed.
-
CLINICAL_TRIALS research · 2025-06-22Clinical Trial Update: An Extension Study for Patients Previously Enrolled in Studies With Pelabresib [Phase 3]
An extension study for patients who previously enrolled in pelabresib studies, currently recruiting in Phase 3 under Novartis.
-
CLINICAL_TRIALS trial_result · 2025-06-19Clinical Trial Update: Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours [Phase 1]
This Phase 1 trial assessed weekly intravenous administration of BI 836845 in Japanese patients with advanced solid tumors. The study is com…